Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 40.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,472 shares of the biotechnology company's stock after selling 34,962 shares during the period. Allspring Global Investments Holdings LLC owned about 0.05% of Sarepta Therapeutics worth $3,125,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. EP Wealth Advisors LLC lifted its position in Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after buying an additional 105 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after buying an additional 145 shares during the period. Virtus ETF Advisers LLC raised its holdings in shares of Sarepta Therapeutics by 6.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company's stock valued at $342,000 after buying an additional 174 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after buying an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after buying an additional 216 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SRPT has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their price objective on Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating for the company in a research report on Tuesday, May 20th. Barclays lowered their price objective on Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating for the company in a research report on Tuesday, June 17th. TD Cowen cut Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price objective for the company. in a research report on Wednesday, June 18th. Piper Sandler cut Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $70.00 to $36.00 in a research report on Monday, June 16th. Finally, Oppenheimer lowered their price objective on Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a research report on Friday, June 20th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Hold" and an average price target of $60.88.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded up $1.27 during trading hours on Tuesday, reaching $18.59. 599,791 shares of the company's stock were exchanged, compared to its average volume of 2,196,242. The company has a market cap of $1.83 billion, a P/E ratio of -6.87 and a beta of 0.45. The company's 50 day moving average is $34.46 and its two-hundred day moving average is $74.09. Sarepta Therapeutics, Inc. has a 1 year low of $16.88 and a 1 year high of $154.90. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business's quarterly revenue was up 80.2% on a year-over-year basis. During the same period last year, the company posted $0.73 earnings per share. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.